2.2.0.7 true Sheet 00 - Document - Document and Entity Information Document and Entity Information http://celgene.com/role/DocumentAndEntityInformation false R1.xml false Sheet 0110 - Statement - Consolidated Statements of Operations (Unaudited) Consolidated Statements of Operations (Unaudited) http://celgene.com/role/StatementsOfOperations false R2.xml false Sheet 0120 - Statement - Consolidated Balance Sheets (Unaudited) Consolidated Balance Sheets (Unaudited) http://celgene.com/role/BalanceSheets false R3.xml false Sheet 0121 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Consolidated Balance Sheets (Unaudited) (Parenthetical) http://celgene.com/role/BalanceSheetsParenthetical false R4.xml false Sheet 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) Consolidated Statements of Cash Flows (Unaudited) http://celgene.com/role/StatementsOfCashFlows false R5.xml false Sheet 0201 - Disclosure - Nature of Business and Basis of Presentation Nature of Business and Basis of Presentation http://celgene.com/role/NatureOfBusinessAndBasisOfPresentation false R6.xml false Sheet 0202 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies http://celgene.com/role/SummaryOfSignificantAccountingPolicies false R7.xml false Sheet 0203 - Disclosure - Acquisition of Gloucester Pharmaceuticals, Inc Acquisition of Gloucester Pharmaceuticals, Inc http://celgene.com/role/Acquisition false R8.xml false Sheet 0204 - Disclosure - Earnings Per Share Earnings Per Share http://celgene.com/role/EarningsPerShare false R9.xml false Sheet 0205 - Disclosure - Comprehensive Income Comprehensive Income http://celgene.com/role/ComprehensiveIncomeLoss false R10.xml false Sheet 0206 - Disclosure - Financial Instruments and Fair Value Measurement Financial Instruments and Fair Value Measurement http://celgene.com/role/FinancialInstrumentsAndFairValueMeasurement false R11.xml false Sheet 0207 - Disclosure - Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities http://celgene.com/role/DerivativeInstrumentsAndHedgingActivities false R12.xml false Sheet 0208 - Disclosure - Cash, Cash Equivalents and Marketable Securities Available for Sale Cash, Cash Equivalents and Marketable Securities Available for Sale http://celgene.com/role/CashCashEquivalentsAndMarketableSecuritiesAvailableForSale false R13.xml false Sheet 0209 - Disclosure - Inventory Inventory http://celgene.com/role/Inventory false R14.xml false Sheet 0210 - Disclosure - Investment in Affiliated Companies Investment in Affiliated Companies http://celgene.com/role/InvestmentInAffiliatedCompanies false R15.xml false Sheet 0211 - Disclosure - Intangible Assets and Goodwill Intangible Assets and Goodwill http://celgene.com/role/IntangibleAssetsAndGoodwill false R16.xml false Sheet 0212 - Disclosure - Share-Based Compensation Share-Based Compensation http://celgene.com/role/ShareBasedCompensation false R17.xml false Sheet 0213 - Disclosure - Income Taxes Income Taxes http://celgene.com/role/IncomeTaxes false R18.xml false Sheet 0214 - Disclosure - Collaboration Agreements Collaboration Agreements http://celgene.com/role/CollaborationAgreements false R19.xml false Sheet 0215 - Disclosure - Commitments and contingencies Commitments and contingencies http://celgene.com/role/CommitmentsAndContingencies false R20.xml false Sheet 0216 - Disclosure - Subsequent Events Subsequent Events http://celgene.com/role/SubsequentEvents false R21.xml false Sheet 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) Summary of Significant Accounting Policies (Policies) http://celgene.com/role/SummaryOfSignificantAccountingPoliciesPolicies false R22.xml false Sheet 0403 - Disclosure - Acquisition of Gloucester Pharmaceuticals Inc. (Policies) Acquisition of Gloucester Pharmaceuticals Inc. (Policies) http://celgene.com/role/AcquisitionOfGloucesterPharmaceuticalsIncPolicies false R23.xml false Sheet 0503 - Disclosure - Acquisition of Gloucester Pharmaceuticals Inc. (Tables) Acquisition of Gloucester Pharmaceuticals Inc. (Tables) http://celgene.com/role/AcquisitionOfBusinessTables false R24.xml false Sheet 0504 - Disclosure - Earnings Per Share (Tables) Earnings Per Share (Tables) http://celgene.com/role/EarningsPerShareTables false R25.xml false Sheet 0505 - Disclosure - Comprehensive Income (Tables) Comprehensive Income (Tables) http://celgene.com/role/ComprehensiveIncomeTables false R26.xml false Sheet 0506 - Disclosure - Financial Instruments and Fair Value Measurement (Tables) Financial Instruments and Fair Value Measurement (Tables) http://celgene.com/role/FinancialInstrumentsAndFairValueMeasurementTables false R27.xml false Sheet 0507 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Derivative Instruments and Hedging Activities (Tables) http://celgene.com/role/DerivativeInstrumentsAndHedgingActivitiesTables false R28.xml false Sheet 0508 - Disclosure - Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Tables) Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Tables) http://celgene.com/role/CashCashEquivalentsAndMarketableSecuritiesAvailableForSaleTables false R29.xml false Sheet 0509 - Disclosure - Inventory (Tables) Inventory (Tables) http://celgene.com/role/InventoryTables false R30.xml false Sheet 0510 - Disclosure - Investment in Affiliated Companies (Tables) Investment in Affiliated Companies (Tables) http://celgene.com/role/InvestmentInAffiliatedCompaniesTables false R31.xml false Sheet 0511 - Disclosure - Intangible Assets and Goodwill (Tables) Intangible Assets and Goodwill (Tables) http://celgene.com/role/IntangibleAssetsAndGoodwillTables false R32.xml false Sheet 0512 - Disclosure - Share Based Compensation (Tables) Share Based Compensation (Tables) http://celgene.com/role/ShareBasedCompensationTables false R33.xml false Sheet 0601 - Disclosure - Nature of Business and Basis of Presentation (Details) Nature of Business and Basis of Presentation (Details) http://celgene.com/role/NatureOfBusinessAndBasisOfPresentationDetails false R34.xml false Sheet 0603 - Disclosure - Acquisition of Gloucester Pharmaceuticals Inc. (Details) Acquisition of Gloucester Pharmaceuticals Inc. (Details) http://celgene.com/role/AcquisitionOfBusinessDetails false R35.xml false Sheet 0604 - Disclosure - Earnings Per Share (Details) Earnings Per Share (Details) http://celgene.com/role/EarningsPerShareDetails false R36.xml false Sheet 0605 - Disclosure - Comprehensive Income (Details) Comprehensive Income (Details) http://celgene.com/role/ComprehensiveIncomeDetails false R37.xml false Sheet 0606 - Disclosure - Financial Instruments and Fair Value Measurement (Details) Financial Instruments and Fair Value Measurement (Details) http://celgene.com/role/FinancialInstrumentsAndFairValueMeasurementDetails false R38.xml false Sheet 0607 - Disclosure - Derivative Instruments and Hedging Activities (Details) Derivative Instruments and Hedging Activities (Details) http://celgene.com/role/DerivativeInstrumentsAndHedgingActivitiesDetails false R39.xml false Sheet 0608 - Disclosure - Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Details) Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Details) http://celgene.com/role/CashCashEquivalentsAndMarketableSecuritiesAvailableForSaleDetails false R40.xml false Sheet 0609 - Disclosure - Inventory (Details) Inventory (Details) http://celgene.com/role/InventoryDetails false R41.xml false Sheet 0610 - Disclosure - Investment in Affiliated Companies (Details) Investment in Affiliated Companies (Details) http://celgene.com/role/InvestmentInAffiliatedCompaniesDetails false R42.xml false Sheet 0611 - Disclosure - Intangible Assets and Goodwill (Details) Intangible Assets and Goodwill (Details) http://celgene.com/role/IntangibleAssetsAndGoodwillDetails false R43.xml false Sheet 0612 - Disclosure - Share Based Compensation (Details) Share Based Compensation (Details) http://celgene.com/role/ShareBasedCompensationDetails false R44.xml false Sheet 0613 - Disclosure - Income Taxes (Details) Income Taxes (Details) http://celgene.com/role/IncomeTaxesDetails false R45.xml false Sheet 0614 - Disclosure - Collaboration Agreements (Details) Collaboration Agreements (Details) http://celgene.com/role/CollaborationAgreementsDetails false R46.xml false Sheet 0616 - Disclosure - Subsequent Events (Details) Subsequent Events (Details) http://celgene.com/role/SubsequentEventDetails false R47.xml false Book All Reports All Reports false 1 149 51 0 4 341 true false NineMonthsEnded_30Sep2009_Other_Income_Member 1 ThreeMonthsEnded_30Sep2010_Sales_Member 1 BalanceAsOf_31Dec2009_British_Pound_Member_Foreign_Exchange_Member 1 OneMonthEnded_30Sep2007_Collaboration_Agreements_Company_One_Member 1 ThreeMonthsEnded_30Sep2009_Other_Income_Member 1 ThreeMonthsEnded_30Sep2010_Share_Based_Compensation_Expense_Member 4 BalanceAsOf_15Oct2010_Senior_Notes_One_Member 2 NineMonthsEnded_30Sep2010_U_S_Government_Agencies_Debt_Securities_Member 2 BalanceAsOf_30Sep2010_British_Pound_Member_Foreign_Exchange_Member 1 TwelveMonthsEnded_31Dec2010 1 NineMonthsEnded_30Sep2010_Development_Member_Collaboration_Agreements_Company_Two_Member 1 BalanceAsOf_31Dec2009_Corporate_Debt_Securities_Member 2 NineMonthsEnded_30Sep2010_Acquired_Developed_Product_Rights_Member 1 BalanceAsOf_31Dec2009_Foreign_Exchange_Member_Others_Member 1 BalanceAsOf_30Sep2010_Acquired_Developed_Product_Rights_Member 3 BalanceAsOf_31Dec2009_Swiss_Franc_Member_Foreign_Exchange_Member 1 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Three_Member 1 BalanceAsOf_15Jan2010 16 NineMonthsEnded_30Sep2009 76 BalanceAsOf_30Sep2010_Stock_Option_Plan_Member 1 BalanceAsOf_30Sep2010_Acquired_In_Process_Research_And_Development_Product_Rights_Member 2 BalanceAsOf_31Dec2009_Other_Non_Current_Liabilities_Member 2 BalanceAsOf_31Dec2009_U_S_Treasury_Securities_Member 2 ThreeMonthsEnded_30Sep2009_Research_And_Development_Member 1 TwelveMonthsEnded_31Dec2009_Mortgage_Backed_Securities_Issued_By_U_S_Government_Sponsored_Enterprises_Member 2 TwelveMonthsEnded_31Dec2012 1 TwelveMonthsEnded_31Dec2009 4 BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level3_Member 5 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Two_Member 2 BalanceAsOf_31Dec2009_Other_Non_Current_Assets_Member 2 NineMonthsEnded_30Sep2009_Share_Based_Compensation_Expense_Member 4 BalanceAsOf_30Sep2010_Fair_Value_Inputs_Level3_Member 6 BalanceAsOf_31Dec2009_Other_Current_Liabilities_Member 4 BalanceAsOf_31Dec2009_Foreign_Government_Debt_Securities_Member 2 TwelveMonthsEnded_31Dec2009_U_S_Treasury_Securities_Member 2 BalanceAsOf_30Sep2010_Collaboration_Agreements_Company_Three_Member 1 BalanceAsOf_30Sep2010_Developed_Technology_Rights_Member 3 NineMonthsEnded_30Sep2010_License_Agreement_Terms_Member 1 OneMonthEnded_31May2009_Collaboration_Agreements_Company_Five_Member 1 BalanceAsOf_30Sep2010_Foreign_Exchange_Member 1 BalanceAsOf_15Jan2010_Product_One_Member 3 BalanceAsOf_30Sep2010_Mortgage_Backed_Securities_Issued_By_U_S_Government_Sponsored_Enterprises_Member 2 BalanceAsOf_30Sep2010_Foreign_Exchange_Member_Japanese_Yen_Member 1 NineMonthsEnded_30Sep2009_Foreign_Exchange_Forward_Member 1 BalanceAsOf_30Sep2010_Foreign_Exchange_Contract_Member_Other_Current_Liabilities_Member 4 BalanceAsOf_31Dec2009_Mortgage_Backed_Securities_Issued_By_U_S_Government_Sponsored_Enterprises_Member 2 BalanceAsOf_30Sep2010_U_S_Government_Agencies_Debt_Securities_Member 2 ThreeMonthsEnded_30Sep2009_Share_Based_Compensation_Expense_Member 4 BalanceAsOf_30Sep2010_Foreign_Exchange_Member_Others_Member 1 NineMonthsEnded_30Sep2010_Restricted_Stock_Member 7 ThreeMonthsEnded_30Sep2010_Research_And_Development_Member 1 NineMonthsEnded_30Sep2010_Discovery_Stage_Programs_Member_Collaboration_Agreements_Company_Three_Member 1 TwelveMonthsEnded_31Dec2009_Corporate_Debt_Securities_Member 2 NineMonthsEnded_30Sep2010_Commercial_Member_Collaboration_Agreements_Company_One_Member 1 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Five_Member_G_I4000_Member 1 BalanceAsOf_31Dec2009_Share_Based_Compensation_Expense_Member 1 NineMonthsEnded_30Sep2010_Stock_Option_Plan_Member 1 BalanceAsOf_30Sep2010_Swiss_Franc_Member_Foreign_Exchange_Member 1 BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level1_Member 5 BalanceAsOf_30Sep2010_Equity_Securities_Member 2 BalanceAsOf_30April2009_Collaboration_Agreements_Company_Five_Member 1 OneMonthEnded_29Feb2008_Collaboration_Agreements_Company_Three_Member 1 ThreeMonthsEnded_30Sep2010 39 ThreeMonthsEnded_30Sep2009 33 NineMonthsEnded_30Sep2010_Developed_Technology_Rights_Member 1 BalanceAsOf_30Sep2010_Foreign_Exchange_Contract_Member_Other_Current_Assets_Member 4 TwelveMonthsEnded_31Dec2009_License_Agreement_Terms_Member 1 TwelveMonthsEnded_31Dec2009_Equity_Securities_Member 1 BalanceAsOf_30Sep2009 3 NineMonthsEnded_30Sep2010_U_S_Treasury_Securities_Member 2 NineMonthsEnded_30Sep2010_Foreign_Government_Debt_Securities_Member 2 NineMonthsEnded_30Sep2010_Equity_Securities_Member 1 BalanceAsOf_31Dec2009_Restricted_Stock_Member 2 NineMonthsEnded_30Sep2010_Development_Member_Collaboration_Agreements_Company_One_Member 1 BalanceAsOf_15Oct2010 16 BalanceAsOf_30Sep2010_Canadian_Dollar_Member_Foreign_Exchange_Member 1 BalanceAsOf_30Sep2010_Foreign_Exchange_Contract_Member_Other_Non_Current_Liabilities_Member 2 BalanceAsOf_15Oct2010_Senior_Notes_Two_Member 2 BalanceAsOf_30Sep2010_Share_Based_Compensation_Expense_Member 1 BalanceAsOf_26Oct2010 1 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Four_Member 4 NineMonthsEnded_30Sep2010_Share_Based_Compensation_Expense_Member 4 OneMonthEnded_30Jun2009_Collaboration_Agreements_Company_One_Member 1 BalanceAsOf_30Sep2010_Corporate_Debt_Securities_Member 2 NineMonthsEnded_30Sep2010_Other_Income_Member 1 BalanceAsOf_30Jun2009 1 NineMonthsEnded_30Sep2010_Research_And_Development_Member 1 BalanceAsOf_31Dec2009_Equity_Securities_Member 2 BalanceAsOf_30Sep2010_License_Agreement_Terms_Member 3 BalanceAsOf_30Sep2010_Foreign_Exchange_Member_Euro_Member 1 BalanceAsOf_30Sep2010_Fair_Value_Inputs_Level1_Member 6 ThreeMonthsEnded_30Sep2009_Other_Income_Member_Foreign_Exchange_Forward_Member 1 NineMonthsEnded_30Sep2010_Other_Income_Member_Foreign_Exchange_Forward_Member 1 NineMonthsEnded_30Sep2009_Other_Income_Member_Foreign_Exchange_Forward_Member 1 BalanceAsOf_31Dec2008 3 TwelveMonthsEnded_31Dec2011 1 BalanceAsOf_30Sep2007_Collaboration_Agreements_Company_Five_Member 1 NineMonthsEnded_30Sep2010_Development_Member_Collaboration_Agreements_Company_Three_Member 1 OneMonthEnded_30Apr2009 1 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Six_Member 4 NineMonthsEnded_30Sep2010_Foreign_Exchange_Forward_Member 1 BalanceAsOf_31Dec2009_Foreign_Exchange_Member_Euro_Member 1 NineMonthsEnded_30Sep2010_Product_Right_Asset_Member 1 OneMonthEnded_31Dec2009_Collaboration_Agreements_Company_Two_Member 1 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Five_Member_Future_Globe_Immune_Programs_Member 1 BalanceAsOf_30Sep2010_Fair_Value_Inputs_Level2_Member 6 BalanceAsOf_31Dec2009_Foreign_Exchange_Member_Japanese_Yen_Member 1 TwelveMonthsEnded_31Dec2009_Acquired_Developed_Product_Rights_Member 1 BalanceAsOf_14Apr2010 4 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Five_Member_G_I6200_G_I3000_And_G_I10000_Member 1 ThreeMonthsEnded_30Sep2010_Foreign_Exchange_Forward_Member 1 NineMonthsEnded_30Sep2009_Sales_Member 1 BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level2_Member 5 TwelveMonthsEnded_31Dec2009_U_S_Government_Agencies_Debt_Securities_Member 2 BalanceAsOf_30Sep2010_Foreign_Exchange_Contract_Member_Other_Non_Current_Assets_Member 2 BalanceAsOf_31Dec2009_U_S_Government_Agencies_Debt_Securities_Member 2 ThreeMonthsEnded_30Sep2010_Other_Income_Member_Foreign_Exchange_Forward_Member 1 BalanceAsOf_30Sep2010_Restricted_Stock_Member 3 NineMonthsEnded_30Sep2010_Commercial_Member_Collaboration_Agreements_Company_Four_Member 1 NineMonthsEnded_30Sep2010_Mortgage_Backed_Securities_Issued_By_U_S_Government_Sponsored_Enterprises_Member 2 BalanceAsOf_31Dec2009_Other_Current_Assets_Member 4 BalanceAsOf_31Dec2009 62 TwelveMonthsEnded_31Dec2013 1 BalanceAsOf_15Jan2010_Product_Two_Member 3 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Five_Member 2 BalanceAsOf_31Dec2009_Foreign_Exchange_Member 1 BalanceAsOf_31Dec2009_Canadian_Dollar_Member_Foreign_Exchange_Member 1 OneMonthEnded_31Oct2010 1 TwelveMonthsEnded_31Dec2009_Foreign_Government_Debt_Securities_Member 2 ThreeMonthsEnded_30Sep2009_Sales_Member 1 BalanceAsOf_31Dec2009_License_Agreement_Terms_Member 3 BalanceAsOf_15Oct2010_Senior_Notes_Three_Member 2 BalanceAsOf_30Sep2010_Foreign_Government_Debt_Securities_Member 2 NineMonthsEnded_30Sep2009_Research_And_Development_Member 1 NineMonthsEnded_30Sep2010_Corporate_Debt_Securities_Member 2 BalanceAsOf_30Sep2010 92 January-01-2010_September-30-2010 159 BalanceAsOf_31Dec2009_Acquired_Developed_Product_Rights_Member 3 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_One_Member 1 BalanceAsOf_31May2009_Collaboration_Agreements_Company_Five_Member 1 BalanceAsOf_30Sep2010_U_S_Treasury_Securities_Member 2 NineMonthsEnded_30Sep2010_Sales_Member 1 BalanceAsOf_31Dec2009_Developed_Technology_Rights_Member 3 TwelveMonthsEnded_31Dec2014 1 ThreeMonthsEnded_30Sep2009_Foreign_Exchange_Forward_Member 1 OneMonthEnded_30Sep2007_Collaboration_Agreements_Company_Two_Member 2 ThreeMonthsEnded_30Sep2010_Other_Income_Member 1 TwelveMonthsEnded_31Dec2009_Developed_Technology_Rights_Member 1 NineMonthsEnded_30Sep2010_Collaboration_Agreements_Company_Four_Member_First_E_U_Approval_Member 1 true true